Real-world use and outcomes of targeted therapy and immunotherapy for adjuvant treatment of BRAF-mutated melanoma patients in the United States

被引:0
作者
Chandrasekaran, Sanjay [1 ]
Ling, You-Li [2 ]
Tang, Jackson [3 ]
机构
[1] Univ Texas Southwestern Med Ctr, Harold C Simmons Comprehens Canc Ctr, Dept Internal Med, Div Hematol Oncol, Dallas, TX 75235 USA
[2] Novartis Pharmaceut, E Hanover, NJ USA
[3] Asclepius Analyt, New York, NY USA
关键词
BRAF-mutated melanoma; immunotherapy; real-world outcomes; targeted therapy; treatment patterns; STAGE-III; INHIBITION; IPILIMUMAB; NIVOLUMAB;
D O I
10.1097/CMR.0000000000000990
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Using a customized, harmonized US electronic health record database, real-world prescription patterns of first-line adjuvant immunotherapy and targeted therapy were retrospectively assessed for BRAFV600-mutated melanoma. Adults with BRAFV600 mutation-positive stage IIIA-D cutaneous melanoma who received first-line adjuvant immunotherapy (nivolumab or pembrolizumab) or targeted therapy (dabrafenib plus trametinib) between 1 January 2014 and 30 August 2020 in the NOBLE database were included. Patients were followed from first-line adjuvant therapy initiation for at least 6 months, until death, progression, follow-up loss, or data cutoff. Primary endpoints were proportion of patients receiving either therapy in first-line and second-line, treatment switching, treatment timing, and status at the end of first-line therapy. Secondary endpoints included discontinuation rates, recurrence-free survival (RFS), and overall survival (OS). Of 318 patients evaluated, 67.6% received nivolumab, 14.2% pembrolizumab, and 18.2% targeted therapy as first-line adjuvant therapy. Median treatment duration was longest for nivolumab (292 days) and shortest for targeted therapy (115 days). Reason for discontinuation was recorded for 195 of 274 patients who discontinued first-line therapy; most common reasons were treatment completion and treatment-related toxicity [87/158 (55.0%) and 29/158 (18.4%), respectively, in immunotherapy-treated patients; 9/37 (24.3%) and 21/37 (56.8%) in targeted therapy-treated patients]. Median RFS and OS for targeted therapy and nivolumab were not reached and were 34.6 and 38.1 months, respectively, for pembrolizumab. These results inform on prescription preferences and clinical outcomes for BRAFV600-mutated melanoma patients in the first-line adjuvant setting.
引用
收藏
页码:457 / 464
页数:8
相关论文
共 35 条
  • [1] Genomic Classification of Cutaneous Melanoma
    Akbani, Rehan
    Akdemir, Kadir C.
    Aksoy, B. Arman
    Albert, Monique
    Ally, Adrian
    Amin, Samirkumar B.
    Arachchi, Harindra
    Arora, Arshi
    Auman, J. Todd
    Ayala, Brenda
    Baboud, Julien
    Balasundaram, Miruna
    Balu, Saianand
    Barnabas, Nandita
    Bartlett, John
    Bartlett, Pam
    Bastian, Boris C.
    Baylin, Stephen B.
    Behera, Madhusmita
    Belyaev, Dmitry
    Benz, Christopher
    Bernard, Brady
    Beroukhim, Rameen
    Bir, Natalie
    Black, Aaron D.
    Bodenheimer, Tom
    Boice, Lori
    Boland, Genevieve M.
    Bono, Riccardo
    Bootwalla, Moiz S.
    Bosenberg, Marcus
    Bowen, Jay
    Bowlby, Reanne
    Bristow, Christopher A.
    Brockway-Lunardi, Laura
    Brooks, Denise
    Brzezinski, Jakub
    Bshara, Wiam
    Buda, Elizabeth
    Burns, William R.
    Butterfield, Yaron S. N.
    Button, Michael
    Calderone, Tiffany
    Cappellini, Giancarlo Antonini
    Carter, Candace
    Carter, Scott L.
    Cherney, Lynn
    Cherniack, Andrew D.
    Chevalier, Aaron
    Chin, Lynda
    [J]. CELL, 2015, 161 (07) : 1681 - 1696
  • [2] [Anonymous], 2018, TAFINLAR DABRAFENIB
  • [3] [Anonymous], 2017, Opdivo nivolumab
  • [4] [Anonymous], 2018, Mekinist trametinib
  • [5] [Anonymous], 2019, Keytruda pembrolizumab
  • [6] SECOMBIT: The best sequential approach with combo immunotherapy [ipilimumab (I) /nivolumab (N)] and combo target therapy [encorafenib (E)/binimetinib (B)] in patients with BRAF mutated metastatic melanoma: A phase II randomized study
    Ascierto, P. A.
    Mandala, M.
    Ferrucci, P. F.
    Rutkowski, P.
    Guidoboni, M.
    Fernandez, A. M. Arance
    Ferraresi, V.
    Maiello, E.
    Guida, M.
    Del Vecchio, M.
    Fierro, M. T.
    Queirolo, P.
    Lebbe, C.
    Helgadottir, H.
    Melero, I.
    Palmieri, G.
    Giannarelli, D.
    Grimaldi, A. M.
    Dummer, R.
    Sileni, V. Chiarion
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S1316 - S1317
  • [7] Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134
    Atkins, Michael B.
    Lee, Sandra J.
    Chmielowski, Bartosz
    Tarhini, Ahmad A.
    Cohen, Gary I.
    Truong, Thach-Giao
    Moon, Helen H.
    Davar, Diwakar
    O'Rourke, Mark
    Stephenson, Joseph J.
    Curti, Brendan D.
    Urba, Walter J.
    Brell, Joanna M.
    Funchain, Pauline
    Kendra, Kari L.
    Ikeguchi, Alexandra P.
    Jaslowski, Anthony
    Bane, Charles L.
    Taylor, Mark A.
    Bajaj, Madhuri
    Conry, Robert M.
    Ellis, Robert J.
    Logan, Theodore F.
    Laudi, Noel
    Sosman, Jeffrey A.
    Crockett, David G.
    Pecora, Andrew L.
    Okazaki, Ian J.
    Reganti, Sowjanya
    Chandra, Sunandana
    Guild, Samantha
    Chen, Helen X.
    Streicher, Howard Z.
    Wolchok, Jedd D.
    Ribas, Antoni
    Kirkwood, John M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (02) : 186 - +
  • [8] Birnbaum B, 2020, Arxiv, DOI [arXiv:2001.09765, 10.48550/arxiv.2001.09765, DOI 10.48550/ARXIV.2001.09765]
  • [9] The future of targeted kinase inhibitors in melanoma
    Caksa, Signe
    Baqai, Usman
    Aplin, Andrew E.
    [J]. PHARMACOLOGY & THERAPEUTICS, 2022, 239
  • [10] Cutaneous Melanoma Version 2.2019
    Coit, Daniel G.
    Thompson, John A.
    Albertini, Mark R.
    Barker, Christopher
    Carson, William E., III
    Contreras, Carlo
    Daniels, Gregory A.
    DiMaio, Dominick
    Fields, Ryan C.
    Fleming, Martin D.
    Freeman, Morganna
    Galan, Anjela
    Gastman, Brian
    Guild, Valerie
    Johnson, Douglas
    Joseph, Richard W.
    Lange, Julie R.
    Nath, Sameer
    Olszanski, Anthony J.
    Ott, Patrick
    Gupta, Aparna Priyanath
    Ross, Merrick, I
    Salama, April K.
    Skitzki, Joseph
    Sosman, Jeffrey
    Swetter, Susan M.
    Tanabe, Kenneth K.
    Wuthrick, Evan
    McMillian, Nicole R.
    Engh, Anita M.
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2019, 17 (04): : 367 - 402